U.S. COMPANY FILING
JOHNSON & JOHNSON — Form 10-Q filed 2025-10-22
Filing text preview
J&J reported Q3 2025 sales of $23.99B, up 6.8% YoY, with net earnings of $5.15B and diluted EPS of $2.12. Nine-month sales reached $69.63B, up 5.0%, net earnings $21.69B. The company completed the $14.5B Intra-Cellular acquisition in April and announced plans to separate its Orthopaedics business in October. A $7.0B reversal of talc reserve was recorded in the nine-month period.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record